BridgeBio Pharma Director Andrew Lo Receives Equity Awards

BridgeBio Pharma, Inc. director Andrew Lo received equity awards on June 22, 2026, including 3,990 restricted stock units (RSUs) and a stock option for 5,277 shares. The RSUs represent a contingent right to receive one share of common stock each and vest in full on June 22, 2027, subject to Lo's continued service on the board. The stock option has an exercise price of $68.92 per share and expires on June 21, 2036, with the same vesting schedule. Following these awards, Lo directly holds 18,079 shares from the RSU grant and 5,277 stock options. Additionally, he indirectly holds 50,583 shares jointly with his spouse. These awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan.